» Articles » PMID: 35814387

Development and Validation of Nomograms to Predict Cancer-Specific Survival and Overall Survival in Elderly Patients With Prostate Cancer: A Population-Based Study

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Jul 11
PMID 35814387
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Prostate cancer (PC) is the most common non-cutaneous malignancy in men worldwide. Accurate predicting the survival of elderly PC patients can help reduce mortality in patients. We aimed to construct nomograms to predict cancer-specific survival (CSS) and overall survival (OS) in elderly PC patients.

Methods: Information on PC patients aged 65 years and older was downloaded from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate Cox regression models were used to determine independent risk factors for PC patients. Nomograms were developed to predict the CSS and OS of elderly PC patients based on a multivariate Cox regression model. The accuracy and discrimination of the prediction model were tested by the consistency index (C-index), the area under the subject operating characteristic curve (AUC), and the calibration curve. Decision curve analysis (DCA) was used to test the clinical value of the nomograms compared with the TNM staging system and D'Amico risk stratification system.

Results: 135183 elderly PC patients in 2010-2018 were included. All patients were randomly assigned to the training set (N=94764) and the validation set (N=40419). Univariate and multivariate Cox regression model analysis revealed that age, race, marriage, histological grade, TNM stage, surgery, chemotherapy, radiotherapy, biopsy Gleason score (GS), and prostate-specific antigen (PSA) were independent risk factors for predicting CSS and OS in elderly patients with PC. The C-index of the training set and the validation set for predicting CSS was 0.883(95%CI:0.877-0.889) and 0.887(95%CI:0.877-0.897), respectively. The C-index of the training set and the validation set for predicting OS was 0.77(95%CI:0.766-0.774)and 0.767(95%CI:0.759-0.775), respectively. It showed that the proposed model has excellent discriminative ability. The AUC and the calibration curves also showed good accuracy and discriminability. The DCA showed that the nomograms for CSS and OS have good clinical potential value.

Conclusions: We developed new nomograms to predict CSS and OS in elderly PC patients. The models have been internally validated with good accuracy and reliability and can help doctors and patients to make better clinical decisions.

Citing Articles

Multivariate logistic regression analysis of the clinical factors influencing locally advanced prostate cancer.

Ke Z, Xu Y, Shu Y, Wang C, Wu B, Zhang B Transl Cancer Res. 2024; 13(2):676-685.

PMID: 38482405 PMC: 10928594. DOI: 10.21037/tcr-23-1680.


Individualized detection of TMPRSS2-ERG fusion status in prostate cancer: a rank-based qualitative transcriptome signature.

Li Y, Su H, Liu K, Zhao Z, Wang Y, Chen B World J Surg Oncol. 2024; 22(1):49.

PMID: 38331878 PMC: 10854045. DOI: 10.1186/s12957-024-03314-8.


A New Online Dynamic Nomogram: Construction and Validation of a Predictive Model for Distant Metastasis Risk and Prognosis in Patients with Gastrointestinal Stromal Tumors.

Wu H, Ding P, Wu J, Sun C, Guo H, Chen S J Gastrointest Surg. 2023; 27(7):1429-1444.

PMID: 37231240 DOI: 10.1007/s11605-023-05706-9.


Genetic characteristics and clinical-specific survival prediction in elderly patients with gallbladder cancer: a genetic and population-based study.

Zhou H, Chen J, Jin H, Liu K Front Endocrinol (Lausanne). 2023; 14:1159235.

PMID: 37152947 PMC: 10160488. DOI: 10.3389/fendo.2023.1159235.


Development and validation of prognostic nomograms in patients with gallbladder mucinous adenocarcinoma: A population-based study.

Xu X, Wang J Front Oncol. 2023; 12:1084445.

PMID: 36591489 PMC: 9795173. DOI: 10.3389/fonc.2022.1084445.


References
1.
Liu Y, Xia Q, Xia J, Zhu H, Jiang H, Chen X . The impact of marriage on the overall survival of prostate cancer patients: A Surveillance, Epidemiology, and End Results (SEER) analysis. Can Urol Assoc J. 2018; 13(5):E135-E139. PMC: 6520053. DOI: 10.5489/cuaj.5413. View

2.
Zhu X, Gou X, Zhou M . Nomograms Predict Survival Advantages of Gleason Score 3+4 Over 4+3 for Prostate Cancer: A SEER-Based Study. Front Oncol. 2019; 9:646. PMC: 6646708. DOI: 10.3389/fonc.2019.00646. View

3.
Thompson I, Pauler D, Goodman P, Tangen C, Lucia M, Parnes H . Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350(22):2239-46. DOI: 10.1056/NEJMoa031918. View

4.
Liu D, Kuai Y, Zhu R, Zhou C, Tao Y, Han W . Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China. Sci Rep. 2020; 10(1):9104. PMC: 7272631. DOI: 10.1038/s41598-020-64073-6. View

5.
Wilt T, Dahm P . PSA Screening for Prostate Cancer: Why Saying No is a High-Value Health Care Choice. J Natl Compr Canc Netw. 2015; 13(12):1566-74. DOI: 10.6004/jnccn.2015.0182. View